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Some pathogens utilize unique routes to enter cells that may evade the intracellular barriers encountered by the typical clathrin-mediated
endocytic pathway. Retrograde transport and caveolar uptake are among the better characterized pathways, as alternatives to clathrin-mediated
endocytosis, that are known to facilitate entry of pathogens and potential delivery agents. Recent characterization of the trafficking mechanisms of
prion proteins and certain bacteria may present new paradigms for strategizing improvements in therapeutic spread and retention of therapy. This
review will provide an overview of such endocytic pathways, and discuss current and future possibilities in using these routes as a means to
improve therapeutic delivery.
© 2007 Elsevier B.V. All rights reserved.
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Studies in gene therapy and drug targeting have brought to
light the importance of identifying cellular and intracellular
barriers to efficient delivery. Accordingly, a broad audience has
been made aware in recent years of the characteristics of a
typical trafficking pathway for many targeted therapeutics. Such
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entry via receptor-mediated endocytosis into clathrin-coated
pits and vesicles, delivery to early endosomes, and passage
through late endosomes/lysosomes where cargo degradation
otherwise takes place [1–3]. Ligand–receptor pairs, viruses and
other pathogens, as well as non-viral gene delivery vectors are
known to enter cells by such routes. If a targeted therapeutic,
such as a gene delivery vector, is to impart therapeutic efficacy,
however, the degradative pathway must somehow be avoided.
Endocytic pathways other than classical clathrin-mediated
endocytosis targeted for the endosomal/lysosomal compartments
have been better characterized in recent years. Such pathways
may offer alternative uptake and trafficking routes for gene
delivery vectors and targeted therapeutics that may avoid the
barriers posed by the classical route. For example, the retrograde
transport pathway, used by plant and bacterial toxins, facilitates
endocytic trafficking from the cell surface to the Golgi, and from
the Golgi to the endoplasmic reticulum (ER), in reverse of
classical secretion [4,5] (Fig. 1). These toxins can then make use
of the cell's own protein auditing system to become transported to
the cytoplasm where the toxic activity can take place.
Endocytosis via caveolae has been well-studied, and the
route by which SV40 and similar pathogens utilize caveolar
uptake for infection has been characterized in recent years [6]. InFig. 1. Retrograde transport of plant and bacterial toxins. Initial binding to a cell-
surface molecule triggers receptor-mediated endocytosis and delivery to early/
sorting endosomes. Toxins may undergo delivery to the TGN from either early
or late endosomes. From the TGN, toxins may transit through the Golgi
cisternae and become transported to the ER through either a KDEL receptor-
dependent or -independent pathway. Alternatively, transport may take place
directly from the TGN to the ER. The toxin is displaced from the ER through a
pore into the cytoplasm where the translation machinery can be accessed.this pathway, caveolar vesicles fuse with caveosomes, which
facilitate prolonged survival of the pathogen in the cell before
transit to the ER, from which nuclear entry can take place for
viral replication (Fig. 3).
Formation of replication-competent vacuoles inside cells is a
strategy used by Brucella and similar pathogens to gain long-
term survival inside host cells [7]. Such a pathway is typified by
endocytosis into pathogen-containing vacuoles, delivery to and
interaction with the ER, followed by formation of an ER-
derived replicative organelle (Fig. 4).
Endocytic pathways may also lead to effective delivery and
spread to neighboring cells. The secretion of exosomes likely
enables prion proteins to be transmitted from cell to cell [8,9]
(Fig. 2).
Why is studying these pathways important for therapeutic
delivery? Delivery to the lysosomal compartment poses one
major barrier to gene and drug delivery. The appeal of using
viruses or viral components in targeted therapeutics is partly due
to the capacity of endosomal escape, and thus avoidance of
lysosomal degradation, by penetrating the membrane of the
maturing vesicle before cargo delivery to the lysosome.
Peptides derived from several types of pathogens have been
used to accomplish the same [10]. Such peptides are thought to
change conformation in response to the acidifying environment
of the endosomal lumen and as a result, interact with the
endosomal membrane by forming pores or destabilizing the
lipid bilayer, thus affording vesicle escape.
In the event that a gene delivery vector escapes the endocytic
vesicle, cytosolic factors still pose additional barriers. The
crowded cytosolic milieu can prevent rapid vector motility to
the nucleus [11] while cytosolic nucleases can degrade the DNA
cargo [12].
“Alternative” endocytic pathways such as those described
above may contribute toward improvements in therapeutic
delivery by facilitating: the avoidance of lysosomal delivery and
degradation; enhanced delivery to a target organelle (such as the
Golgi, ER, or nucleus) or compartment (such as the cytoplasm);
and enhanced long-term therapy, such as the formation of an
extranuclear replicating organelle.
It is clear that there is more than one route for entering a cell
and studies on a variety of pathogens show that alternative
endocytic pathways have been cleverly hijacked to avoid a
degradative fate and evade the cell's defenses. Here we will
examine some of these pathways, which may serve as possible
routes for improving therapeutic delivery.
2. Retrograde trafficking of plant and bacterial toxins
Plant toxins, such as ricin and abrin, and bacterial toxins,
such as Shiga toxin (STx), cholera toxin (CTx), and Pseudo-
monas exotoxin A (PEx), enter cells following a route in reverse
of the classic secretory pathway [13]. Classical secretion is
characterized by transport of newly synthesized proteins from
the ER to the Golgi, followed by budding of vesiculated cargo
from the trans-Golgi network, vesicle sorting in the cytoplasm,
and fusion with the plasma membrane. While many types of
viruses and similar pathogens can directly access the cytoplasm
Fig. 2. Exosome-mediated spread of prion protein. Prion protein (PrP) may undergo either clathrin or caveolae-mediated endocytosis into early/sorting endosomes
which can sort to multivesicular bodies (MVBs), into which intraluminal vesicles (ILVs) containing cytosolic material bud off into the endosomal lumen. ILV
formation results in GPI-attached proteins remaining anchored at the outer surface of the ILV. MVBs can fuse with either lysosomes or with the plasma membrane,
releasing the ILVs from the cell surface, which are now known as exosomes. Exosomes can either directly fuse with the plasma membrane of an uninfected cell (shown
in green) or undergo endocytic uptake. Direct fusion may result in delivery of PrP to the membrane of endosomal vesicles, which may undergo ILV budding and result
in the location of PrP on the ILVouter surface. Alternatively, endocytosed exosomes may undergo back-fusion with the endosomal limiting membrane, resulting in PrP
localizing to the endosomal membrane.
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retrograde route of classical secretion to accomplish the same.
Certain plant and bacterial toxins share a common structure
comprised of two major domains or chains, termed A and B.
The A chain forms the catalytic or toxic domain, whereas the B
chain is responsible for cell binding [14]. The pro-form of the
protein is non-toxic, whereas proteolytic cleavage inside the cell
activates the toxin after cell entry. In PEx and ricin, this
cleavage releases the A subunit, whereas in CTx and STx, the A
subunit is separated into A1 and A2 chains.
The targets of toxic activity are specific components of the
protein synthesis machinery. The A chains of Stx and ricin are
RNA N-glycosidases that remove a conserved adenine residue
from 28S rRNA that is the site of interaction with elongation
factor (EF)-2 ternary complex [15,16]. The effect is inhibition
of protein synthesis, leading to cell death. The CTx A chain is
an ADP-ribosyltransferase, that modifies the heterotrimeric G
protein Gs-α to activate adenylyl cyclase [17], inducing
intestinal chloride secretion [18]. The Pseudomonas exotoxin
A chain ADP-ribosylates EF-2, preventing protein synthesis
and leading to cell death [19]. As toxic activity requires
interaction with protein synthesis molecules, these toxins
depend on delivery to the cytoplasm to access this machinery.
2.1. Mechanism of toxin entry and trafficking
Consistent with most pathogen infection mechanisms, toxin
cell entry is enabled by binding to a cell-surface molecule, thus
triggering endocytic uptake. Infection by STx and CTx is
initiated by B chain binding to host cell membrane glycolipids.STx binds the trisaccharide domain of globotriaosylceramide
(Gb3/CD77) [20–22], whereas CTx binds the ganglioside, GM1
[23,24]. The PEx B chain binds α2-macroglobulin receptor/low-
density lipoprotein receptor-related protein [25]. The ricin B
chain is a lectin that binds β1-4 linked galactosides, which are
displayed on a wide range of cell-surface glycoproteins and
glycolipids, thus owing to the promiscuity of ricin [26].
Cell-surface binding triggers internalization of the toxins into
endocytic vesicles, which undergo lumen acidification as the
vesicles mature to late endosomes (Fig. 1). Typically, cargo of
late endosomes would become degraded due to vesicle fusion
with lysosomes, which contain proteolytic enzymes. Vesiculated
toxins evade this fate by transit to the TGN from either early or
late endosomes (Fig. 1). These pathways are dependent, at least
in part, on lipid association, certain Rabs, and specific vesicle
and TGN receptors known as SNAREs (soluble N-ethylmalei-
mide-sensitive fusion attachment protein receptors).
Association with lipid rich membrane domains is a common
mode of cell uptake, and accordingly, STx and CTx associate
with detergent resistant membrane microdomains (DRMs) [27]
and undergo transport from early endosomes. PEx, on the other
hand, undergoes lipid-independent transport from late endo-
somes to the TGN [28]. While the late endosome pathway used
by PEx is dependent upon the small GTPase, Rab9 [29],
transport from early endosomes to the TGN is a Rab9-inde-
pendent route used by CTx, STx, and ricin [30].
Transport of cargo from endocytic vesicles to target
organelles entails the fusion of vesicle and target membranes,
which requires interaction of specific vesicle and target mem-
brane SNAREs (or v-SNAREs and t-SNAREs, respectively).
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to TGN pathways depend on the contributing SNAREs, as
each route is characterized by its own separate v-SNAREs and
t-SNAREs [31,32].
Once vesiculated toxins reach the TGN, the cargo is
transported to the endoplasmic reticulum (ER) via several
routes (Fig. 1). One is through the Golgi cisternae by interaction
with the KDEL receptor, which cycles between the TGN and
ER in a coatamer protein complex (COP-1)-dependent manner
[33–35]. The COP1 protein complex, which coats vesicles
budding from the Golgi apparatus, can sort vesiculated cargo
based on interactions with the cytoplasmic domains of
membrane proteins. The KDEL receptor recognizes and binds
KDEL motifs on cargo proteins, and is responsible for
retrieving escaped ER proteins from the Golgi. PEx contains
a KDEL-like sequence that is exposed after A chain release by
furin cleavage in early/recycling endosomes [28,36–39]. The
lipid-sorted pathway, used by STx, is both KDEL receptor and
COP1-independent, and controlled by Rab6 [40–43]. PEx may
also use this pathway [28]. A third poorly characterized
pathway bypasses the Golgi cisternae and instead transports
cargo directly from the TGN to the ER in a KDEL receptor and
COP1-independent manner. CTx uses this pathway, despite the
existence of a KDEL motif in its peptide sequence [44]. It is
possible that this motif functions to retain CTx in the ER after
delivery, and prevent possible anterograde transport to the
Golgi.
Ricin may utilize all 3 pathways. While ricin lacks a KDEL
sequence, evidence shows that it can bind the chaperone,
calreticulin, which has a KDEL motif, and undergoes COP1-
dependent trafficking to ER [45]. Ricin can elicit cell death
when both the classical COP1-dependent and Rab6-dependent
pathways are inhibited, suggesting that ricin can bypass Golgi
stacks along a similar pathway as CTx [46]. As ricin can bind
glycolipids containing a terminal galactose, it may also follow a
lipid-sorting pathway.
Once the toxins have reached the ER, it is thought that the
cytoplasm is accessed by taking advantage of the protein auditing
system in the ER known as ERAD (ER-associated protein
degradation). Thismechanism eliminatesmisfolded proteins from
the ER by discard into the cytoplasm through a pore known as the
Sec61 translocon (now termed a dislocon) [47,48] (Fig. 1).
Typically, such proteins are ubiquitinated and targeted to the
proteasome for degradation. However, toxins contain abnormally
low lysine content, thus are poor substrates for ubiquitination
[49], and hence are spared from degradation but survive in the
cytoplasm to access the protein synthesis machinery.
2.2. Retrograde trafficking for cytosolic delivery of
therapeutics?
Similar types of bacterial toxins, such as diphtheria toxin,
can directly penetrate from the endosomal membrane into the
cytosol, thus avoiding the retrograde route altogether [4]. This
feature has been utilized for the delivery of exogenous genes
[50] and peptides [51,52] into the cytoplasm. Gene delivery
conjugates have also been produced and tested that make use ofcomponents from toxins, like PEx, that undergo retrograde
trafficking. For example, multidomain fusion proteins contain-
ing the translocation domain of PEx have been used to deliver
genes into the cytosol [53,54]. Whether these conjugates
actually trafficked in similar fashion to wild-type PEx is
unknown, though it appears that the intention of the molecular
design was to breach the endosomal membrane. Shiga toxin and
cholera toxin, which also enter the cytoplasm from the ER, have
been tested as gene transfer agents [55–58], though, like PEx
derived vectors, it is not clear whether these agents traffic as the
wild-type toxins when used for gene delivery.
Protein toxins have also been used to generate specific
cytotoxic T lymphocyte (CTL) activation against certain epitopes
[59,60]. Delivery of antigenic peptides by fusion to modified
toxins has facilitated cytosolic entry of antigens, which can then
be degraded in the proteasome and displayed on MHC class I
molecules to prime aCTL response. This approach to generating a
new type of vaccine has been used to deliver epitopes via PEx
[61], STx [62], and other types of toxins [14]. As the molecular
players of the toxin/retrograde trafficking pathway are better
characterized, it may be possible to utilize this route as a means to
target compounds to the other specific organelles contributing to
this pathway. One could envisage the design of new molecules
that can interact with target cells similarly to the toxins discussed
here, and mimic the toxin trafficking pathway to deliver peptides
specifically to the Golgi or ER to, perhaps, correct a defect, or
elicit toxicity for the treatment of cancer. Moreover, given its
avoidance of the lysosome, perhaps this route could be of better
use for gene delivery and enable greater survival of gene therapy
vectors after target cell entry.
3. Prion protein trafficking and intercellular delivery
The cellular prion protein (PrPc) is a glycosylphosphatidy-
linositol (GPI)-anchored protein that is ubiquitously expressed,
though found at higher levels in neurons, some non-neuronal
tissue, and immune cells [63,64]. The function of PrPc remains
unclear, but is thought to contribute to: copper and/or zinc ion
transport or metabolism, protection from oxidative stress,
cellular signaling, membrane excitability and synaptic trans-
mission, apoptosis, and neurite outgrowth. The diseases
associated with prions occur when PrPc undergoes conversion
to a scrapie form (PrPsc) [65,66], resulting from the transcon-
formation of an α-helix to β-sheet-rich structure. PrPsc can seed
further conversion reactions, thus greatly increasing the rate of
transconformation [67]. The resulting molecules can oligomer-
ize into an amyloid fibril, and acquire the tendency to form
amyloid deposits in brain tissue.
In humans, 15% of prion diseases are inherited, due to
mutation in the prion protein gene. The infectious form, which
causes Kuru and Creutzfelt–Jakob disease in humans, scrapie in
sheep, and bovine spongiform encephalopathy in cattle, is
thought to enter the host through the gastrointestinal tract and
become acquired by peripheral nerves and lymphoid tissue
where replication takes place [68,69]. Invasion of the central
nervous system is likely due to transfer via phagocytic mono-
nuclear cells [70,71]. The transfer of the infectious agent from
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are vesicles that are secreted from the cell surface.
3.1. Mechanism of intracellular and intercellular transport
After synthesis, PrPc is secreted to the cell surface where
its GPI anchor is inserted at plasma membrane lipid rafts
[73,74], which are domains within the lipid bilayer exhibiting
a more ordered assembly of specific lipids (usually glyco-
sphingolipids and cholesterol) compared to surrounding
plasma membrane [75]. PrPc can constitutively endocytose
via either clathrin-coated vesicles or caveolae (Fig. 2), likely
depending on cell type or lipid microenvironment [74]. Once
internalized, PrPc traffics through late endosomes/lysosomes,
with a steady state fraction localized to multivesicular bodies
(MVBs) in neurons, brain, and non-neuronal cells [76–78].
MVBs are formed by the pinching off of cytosol-filled, or
intraluminal vesicles (ILVs) into the endosomal lumen [79,80]
(Fig. 2). The sorting of cargo into ILVs involves at least 18
proteins and is a tightly regulated process [81]. Among the
cellular factors contributing to this process is the Endosomal
Sorting Complex Required for Transport (ESCRT) machinery,
which are cytosolic proteins that selectively sort cargo to ILVs
[81]. In this process, ubiquitinated cargo proteins are
recognized by Hrs complex (or ESCRT-0) proteins, which
then recruit Tsg101 and the ESCRT-I complex, that also
recognize ubiquitinated cargo. Tsg101 then recruits ESCRT-
III via ESCRT-II or Alix, which together sequester cargo
proteins into the inward-budding ILVs.
MVBs can either fuse with the lysosome or with the plasma
membrane. Plasma membrane fusion enables the release of
ILVs (now known as exosomes) extracellularly (Fig. 2).
Exosomes may serve as a mode of intercellular communication,
a means to discard proteins, and may be exploited by pathogens
for disease transmission [82]. Both PrPsc and PrPc have been
detected in cell culture supernatants, associated with secreted
exosomes [9]. These exosomes elicited conversion of endog-
enous PrPc to PrPsc when incubated with naïve host cells [72],
and caused acute typical neuropathology when inoculated into
mice [9]. These findings suggest that exosomes may facilitate
transfer of infectious prion agent.
Once released, exosomes may transport associated cargo to
remote as well as neighboring cells, which likely explains how
prions may be delivered to sites distant from the site of
introduction. Transfer of the protein to recipient cells is thought
to take place by interaction of exosomes with recipient cell
membranes through two possible types of mechanisms (Fig. 2).
One mechanism is the direct fusion of exosomes with the plasma
membrane, thus transferring contents of exosomalmembranes to
the plasma membrane. This has been suggested by the
observation that recipient cells receive incoming PrPsc into
recipient raft domains, and exchange of membrane components
can take place between exosomes and recipient cells [83]. A
more likely mechanism, however, is that exosomes undergo
endocytic uptake into recipient cells, then back-fuse with the
limiting membrane of the endocytic vesicle, thus transferring
exosomal membrane contents. Exosomal delivery of transcon-formation activity is supported by this mechanism, as the
conversion process is thought to occur at low pH [84,85].
3.2. Exosomes for therapeutic spread?
Gene therapy treatment of solid tumors relies on efficient
delivery to as many cells as possible to obtain the most potent
level of gene expression and potential tumor ablation. However,
delivery of a gene to 100% of cells in a tumor may be an
improbable task. Expression of a gene product that can
somehow spread a therapeutic effect to neighboring cells is a
more feasible approach. Thus, the use of the herpes simplex
virus thymidine kinase (HSV-TK) gene as a therapeutic
transgene has sustained great appeal in gene therapy due to
the ‘bystander effect’ caused by the toxic enzyme product [86].
This effect describes the ability of the HSV-TK enzyme product,
triphosphorylated ganciclovir, to spread to neighboring cells via
gap junctions within the solid tumor, whereas the substrate has
no such effect on cells. More recently, attempts have been made
to enhance this effect by producing TK as a recombinant fusion
to the VP22 protein [87], which has an ability to become
secreted from the expressing cell and taken up by neighboring
cells through a mechanism that remains unclear [88,89]. The
capacity of secreted exosomes from a ‘producer’ cell to be taken
up by neighboring as well as remote cell targets could be a
potent means of delivering the most efficient levels of a
therapeutic to cell targets. One could envisage the ability to
modify such exosomes with a membrane bound targeting ligand
to perhaps limit the spread of a therapeutic to surrounding tumor
tissue while at the same time target remote, metastatic tumors.
Such modified exosomes containing a therapeutic protein or
compound could efficiently deliver the therapy into recipient
cells by fusion of the exosomal membrane with recipient cell
membranes, thus releasing the product directly into the target
cells. Further characterization of the pathogenic and cellular
factors contributing to this process would determine whether
this approach to therapeutic dissemination could be a feasible
option in the future.
4. SV40 trafficking via caveolae and caveosomes
Caveolae are flask-shaped invaginations at the plasma
membrane [90] characterized by a coat comprised mostly of
caveolin-1 (Cav1) [91,92], which is a palmitylated, cholesterol-
binding protein [93,94]. Caveolae regulate several different
signaling cascades, thus caveolin defects can contribute to a
broad range of diseases, including cancer, cardiovascular
disease, diabetes, atherosclerosis, pulmonary fibrosis, and
muscular dystrophies [95]. Certain mammalian viruses, such
as polyomaviruses, influenza viruses, coronaviruses, and
echovirus, use caveolae-mediated transport from the cell surface
to enter cells [96–100]. The trafficking of simian virus 40
(SV40), a non-enveloped DNAvirus of the papovavirus family,
has been most extensively studied, and follows a pathway of
caveolae-mediated transport that facilitates nuclear delivery of
the virus while avoiding the endosomal/lysosomal degradation
route [101–104].
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SV40 binds two receptors. One is ganglioside GM1, located
in lipid rafts [105], and the other is major histocompatibility
(MHC) class I [106]. Virus binding induces receptor clustering,
and sequestration of lipid rafts and associated receptor/virus
complexes into caveolae [107,108] (Fig. 3). Binding also
induces a cascade of signaling events, including tyrosine kinase
phosphorylation and protein kinase C activation [101,109],
which contribute to caveolar formation and endocytosis. One
downstream effect of signaling is actin depolymerization, which
facilitates caveolar internalization, and recruitment of dynamin-
2 to pinch off the caveolar neck and release caveolar vesicles
[104], which some have termed ‘cavicles’ [110]. MHC class I
molecule is not endocytosed with the virus [107].
After release from the cell surface, caveolar vesicles require
intact microtubules to traffic within the cell [110], suggesting
that dynein motors may contribute to motility. These vesicles
may fuse with endosomes from the clathrin-mediated pathway
[111], or with caveosomes [101], which are Cav1-positive, pH
neutral compartments rich in cholesterol and glycosphingoli-
pids [101] (Fig. 3). In non-infected cells, these compartments
are likely to serve as intermediate depots for transport of
sphingolipids and GPI-linked proteins from the plasma mem-
brane to the Golgi apparatus [112,113]. After delivery to
caveosomes, SV40 can be retained in these compartments for
several hours. This contrasts with findings from uninfected cells
showing that caveosomes may mediate receptor turnover
[114,115], and suggests that delivery to and function of
caveosomes depends on the protein cargo.
SV40-containing caveosomes are sorted by Cav1-negative
carriers that traffic along microtubules to the ER [101,116]Fig. 3. Trafficking via caveolae and caveosomes. SV40 bound to the cell surface
can distribute to caveolae, which can pinch off to form a vesicle that is released
from the cell surface and transported to Cav1-positive caveosomes. Alternatively,
SV40 may directly internalize via lipid rafts and fuse with caveosomes. COP1-
mediated transport facilitates delivery from caveosomes to the ER, from which
SV40 possibly exits into the cytosol and enters the nucleus via nuclear pores.(Fig. 3). COPI and COPII-coated carrier vesicles may contribute
to this process. It is thought that SV40 somehow penetrates into
the cytosol after delivery to the ER, from which nuclear entry is
gained via the nuclear pore complex [117] (Fig. 3). In an
alternative and more rapid endocytic pathway, SV40 may be
directly internalized via lipid rafts in a dynamin-2-independent
manner and vesiculate into Cav1-negative organelles [102].
This pathway was identified because SV40 could infect
caveolin-1 knock-out mouse cells.
The molecular mechanisms contributing to caveolar-mediat-
ed trafficking remain to be fully characterized. Even the role of
caveolin is unclear. Expression of Cav1 in cells lacking caveolae
is sufficient to generate caveolar formation [118], whereas
overexpression of Cav1 can inhibit this [119]. It has been
proposed that Cav1 stabilizes caveolar invaginations whereas
Cav1-negative intermediates can rapidly bud from the cell
membrane and endocytose [115]. This may partly explain
findings using green fluorescent protein (GFP)-tagged Cav1
showing that a large pool of immobile caveolin exists in cultured
cells [120]. Such reports in addition to the SV40 trafficking
pathway have suggested that caveolaemediate slow (up to 1–2h)
endocytosis that requires sequestration of cargo at the cell
surface before internalization [101]. This contrasts with the rapid
endothelial transcytosis mediated by caveolae in vivo that has
been observed using specific targeted nanoparticles [121]. These
studies demonstrated that in vivo circulating particles targeted to
caveolae rapidly crossed the endothelium and underlying
basement membrane, and accumulated into the interstitial
space at lung tissues within minutes. The contrasting findings
of the latter and former studies may depend on whether the
studies are being performed in vivo or in cultured cells, as well as
the type of probe being used.
4.2. Caveolar uptake to avoid lysosomal degradation of
therapeutics?
Trafficking studies on non-viral gene delivery vectors have
shown that such vectors may enter the same cells using multiple
cell entry routes [122,123]. Some of these routes may support
delivery to the degradative pathway, while the caveolar route
used by SV40 may not only spare cargo from degradation but
enable prolonged residence in the cell for a period of time before
routing to the ER. Given that cellular proteins, such as
transforming growth factor β receptor (TGFβ-R), elicit receptor
signaling when internalized via clathrin-coated pits whereas
caveosome uptake promotes receptor turnover [114], it appears
that using caveosomes as a means to evade degradation would
depend on modulation by the vesicle cargo itself. In this regard,
further studies characterizing the molecular interactions be-
tween pathogens like SV40 and the host cell that enable
pathogen survival in caveosomes would be useful.
It has been shown that particles resembling non-viral gene
delivery vectors can utilize either clathrin or caveolar-mediated
uptake into cells, depending on particle size [124].While the same
vector or protein may enter the same cells via different routes,
some routes appear to support gene transfer while others do not.
Accumulating studies on vector trafficking do not show, however,
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recent studies have shown that certain polyplexes entered cultured
cells by both clathrin and caveolar-mediated pathways, yet the
latter pathway preferentially led to gene expression whereas
inhibition of the former pathway had no effect [125]. The reverse
was observed for histidinylated polyplexes, whereby clathrin-
mediated endocytosis appeared to preferentially support gene
expression even though the vector entered cells by both clathrin
and non-clathrin-mediated pathways [126].
Recent studies showing that caveolae mediate the rapid
transcytosis of targeted particles across the endothelium, thus
enabling access to deep tissue cells in vivo [121], demonstrate
that it is possible to overcome the endothelial barrier and target
tissue from the circulation. While it has been suggested that
tumor vasculature can be ‘leaky’, and thus facilitate accumu-
lation of therapeutics into a solid tumor, normal tissue,
containing different types of endothelium, may not be as easily
accessible. Thus, targeting to endothelial cell-surface proteins
for the transport of molecules across the vessel wall would be an
important strategy for drug and gene delivery.
5. Vacuole and replicative organelle formation by Brucella
Some pathogens acquire prolonged survival in a host cell by
forming a vacuole in which the pathogen resides and evades
the host defenses. Among the bacterial pathogens that share
a similar vacuole trafficking mechanism are: Shigella, Lis-
teria, Mycobacterium, Salmonella, Legionella, Francisella,
and Brucella [127,128]. The trafficking of Brucella is among
the most extensively studied, and characterized by endocytosis
into a special vacuole that interacts with the ER and forms
a replicative organelle in which the bacterium establishes
long-term survival. Brucella replicates inside infected host
cells, such as macrophages [129], and causes brucellosis,Fig. 4. Vacuole and replicating organelle formation. Membrane-bound Brucella is in
early/sorting endosomes, or undergo maturation, which entails transit to the ER. Inte
undergoes maturation to a replicative organelle.which can affect a broad range of mammals, including
livestock and humans [130]. Human brucellosis can be a
chronic and debilitating disease, and the long-term survival of
Brucella in host cells contributes to disease chronicity. Chla-
mydia also forms pathogen-containing vacuoles after cell
entry. C. pneunomiae (Cpn) is associated with respiratory tract
infections, including pneumonia, asthma, bronchitis, sinusitis,
and sarcoidosis [131].
5.1. Brucella trafficking
Brucella infection is initiated by binding of bacterial surface-
exposed Hsp60 to the cellular prion protein, PrPc [132]. While
PrPc may typically undergo clathrin-mediated endocytosis,
Brucella is somehow able to modulate its own endocytic uptake
and avoid targeting to the lysosomal degradation pathway
[133]. Instead, it is thought that uptake occurs via lipid raft
endocytosis, as lipid raft disruption affects cell entry, short-term
survival and replication of Brucella suis and Brucella abortus
[134].
Endocytic uptake results in the formation of a Brucella-
containing vacuole (BCV) (Fig. 4), which can interact with early
endosomes but avoids fusion with late endosomes/lysosomes, as
observed by the absence of GTPase Rab7 and other late
endosomal markers from the vacuole [135,136].While BCV can
acquire LAMP-1, it is argued that other compartments in
addition to late endosomes/lysosomes can harbor the LAMP-1
marker [137]. As the BCV vacuole matures, it undergoes
acidification [138], and comes in close contact with the ER [129]
(Fig. 4). The BCV interacts with the ER and forms an ER-
derived replicative organelle, establishing long-term survival
(Fig. 4). In epithelial cells, the replicative organelle is ER-
derived, whereas in phagocytic cells, BCVs dock at the ER and
acquire ER-specific markers via limited fusion events [129]. Atternalized into a Brucella-containing vacuole (BCV), which can either fuse with
ractions with the ER can result in acquisition of ER markers, while the vacuole
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replication. Requirement for additional membrane output for
replication is likely provided by further fusion interactions with
the ER membrane. Studies on L. pneumophila show that
biogenesis of the ER-derived organelle requires interception of
COPI vesicular trafficking from the ER [139]. This is not true for
Brucella, however, as blocking such trafficking has no effect on
BCV maturation or replication [129].
The molecular mechanism of entry and survival is still
unclear, though VirB protein has received much attention. The
screening of Brucella survival mutants generated by transposon
insertion identified the VirB operon [140], which encodes a type
IV-related secretion system that typically secretes/exports
nucleoprotein complexes or proteins [129,141]. In contrast to
wild-type Brucella, the VirB mutants undergo lipid raft-
independent endocytosis, remain in immature vacuoles, can
dock with the ER but do not sustain fusion with the ER, and are
ultimately targeted to the degradative pathway (thus failing to
reach a replicative niche). The relevance of VirB in endocytic
entry is unclear, as a minority of ingested wild-type bacteria
survive in the host cell, suggesting that the majority of
internalized bacteria do not escape the degradative pathway
[129,142,143]. Furthermore, studies in B. suis show that VirB
expression takes place after cell entry [144]. VirB is likely
involved in late events corresponding with ER fusion [129].
It is possible that VirB mediates the transport of bacterial
effector molecules into the host cell that may modulate BCV
maturation.
5.2. Vacuologenesis for extranuclear replication and retention
of therapeutics?
Gene therapy may be administered as a temporary, short-
term treatment for a disease, such as cancer, or as a long-term or
permanent solution to replace or correct a defective gene. Long-
term approaches have typically entailed the use of a viral vector
with the capacity to integrate a gene of interest into the host
genome, which can pose serious concerns, including the
possibility that gene insertion can activate an oncogenic effect
[145–147]. Alternatively, DNA vectors containing elements for
extrachromosomal retention in host cells may support a long-
term, though not permanent, solution for transgene delivery
[148]. In the same vein, perhaps an extranuclear organelle, such
as the type of vacuole providing a haven for pathogens like
Brucella, may enable the long-term residence and retention of
a gene therapy vector or drug in a target cell. Bacterial-like
vectors have been considered for cancer therapy and gene
therapy [149–151]. While the mechanism for the formation of
pathogen-containing vacuoles and replicative organelles needs
further characterization, studies so far appear to suggest that
these intracellular bodies occur as a result of interaction
between pathogen gene products and host cell factors. Further
studies identifying the players in these interactions and
associated functions may direct future efforts to design
molecules that can mimic these dynamics and induce the for-
mation of similar intracellular organelles. One could envisage
such organelles as being useful in the long-term intracellularretention of therapeutic compounds or genes, whose release
over time could be of more benefit in comparison to large,
potentially toxic, bolus doses of therapeutic that may require
numerous repeat doses to be effective.
6. Conclusion
In the development of drug and gene delivery, directing the
entry and trafficking of therapeutics to specific intracellular
pathways is a worthwhile consideration. While the typical
clathrin-mediated endocytic pathway used by many gene
therapy vectors and targeted therapeutics introduces common
cellular barriers, alternative pathways such as those discussed
here may provide a means to evade such barriers. Moreover,
such pathways may facilitate delivery to specific organelles and
cellular compartments. Future studies on the molecular mech-
anisms mediating pathogen trafficking through these pathways
may enable design of new vectors and delivery agents with
improved ability to direct therapy to desired intracellular targets.
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